Navigation Links
BioMed Central welcomes the new National Institutes of Health public access policy

Yet another follow up of the NIH public access policy announced earlier this week, this time from free-access publisher BioMed Central :

BioMed Central welcomes the announcement of the US National Institutes of Health (NIH) new public access policy. The NIH calls on all of its grantees to deposit articles resulting from their NIH-funded research in the National Library of Medicine's PubMed Central and make them freely available within 12 months.

BioMed Central anticipates that many other funding bodies worldwide will now follow the example set by NIH.

All NIH grantees now have a new factor to take into account when choosing where they wish to publish their research. To fulfil the NIH request, authors publishing with most of the traditional subscription publishers will be expected to go through a process of resubmitting their papers to the PubMed Central repository. In addition, they will often need to update their manuscript version with the changes introduced in the publication process, as many publishers specify that only the author's version of the manuscript can be submitted to archives.

Those who choose to publish in any of BioMed Central's Open Access journals, which cover all areas of biology and medicine, are assured that the published version of their paper will be placed in PubMed Central for them, immediately and without any need for additional work from them. Researchers are thus saved the time and effort of going through the deposition process themselves.

This significant benefit is in addition to the rapid and high quality peer review, fast publication and high visibility of BioMed Central's Open Access journals.

BioMed Central urges all researchers in the life and medical sciences to fulfil the NIH request and to submit their future manuscripts to one of the 130 Open Access journals publishe d by BioMed Central.


'"/>

Source:BioMed Central


Related biology news :

1. BioMed Central launches Biology Direct
2. Impressive new Impact Factors for BioMed Centrals open-access journals
3. Ariadne Genomics Announces the Release of PathwayStudio?Central, Client-Server Software for Biological Pathway Analysis
4. Parts of the Caribbean and Central America are likely to have less summer rain
5. Papers of DNA Pioneer and Nobel Laureate Francis Crick Added to National Library of Medicine’s Profiles in Science Web Site
6. National Academies advisory: Invasive aquatic species in the Great Lakes
7. Virginia Bioinformatics Institutes launches microbial database
8. OneWorld Health drug receives Orphan designation from U.S. and European regulatory agencies
9. Health costs soar as 60 million Americans classed as obese
10. Going To Extremes To Improve Human Health
11. Patient-choice C-section rate rises 36%: HealthGrades study
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/13/2016)... April 13, 2016  IMPOWER physicians supporting Medicaid patients ... a new clinical standard in telehealth thanks to a ... the higi platform, IMPOWER patients can routinely track key ... body mass index, and, when they opt in, share ... visit to a local retail location at no cost. ...
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016   EpiBiome , a precision microbiome ... in debt financing from Silicon Valley Bank (SVB). The ... to advance its drug development efforts, as well as ... "SVB has been an incredible strategic partner to ... traditional bank would provide," said Dr. Aeron Tynes ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the ... Convention Center and will showcase its product’s latest features from June 26 to ... a scientific poster on Disrupting Clinical Trials in The Cloud during the conference. ...
(Date:6/23/2016)... , June 23, 2016 ... research report to its pharmaceuticals section with historic ... details and much more. Complete report ... 151 pages, profiling 15 companies and supported with ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global ...
Breaking Biology Technology: